Despite the success of immune checkpoint blockade of PD-1 or PD-L1 in cancer immunotherapy, the molecular mechanism of PD-1 triggering as to how ligand binding translates into biochemical signaling remains poorly understood. The gene discussed is PDCD1; the disease is cancer.